RESULTS: 20.85% patients (nϭ108) showed biofilm formation. Compared to patients without biofilms, patients with biofilms were significantly more likely to have asthma, use nasal steroids, oral steroids, nasal irrigation, have prior sinus surgeries, and were older. Positive culture results were significantly correlated with biofilm formation (spearman's ϭ0.1597, pϭ0.0009). However, presence of polyps, allergy, smoking, diabetes, sleep apnea, gender and current antibiotic use were not significantly different between the 2 groups. After adjusting all the clinical factors in multiple logistic regression models, patients who had prior sinus surgeries were 2.35 times more likely to have bacterial biofilm present (odds ratio 95% confidence interval 1.25, 4.45, pϭ0.008). CONCLUSION: After controlling for many clinical factors related with persistent CRS, prior sinus surgeries are still significantly associated with bacterial biofilm formation. This provides evidence that bacterial biofilm is an independent risk factor for the recurrent and resistant nature of some forms of CRS.
OBJECTIVE: Understand the cost burden and utilization of health care for chronic rhinosinusitis (CRS). METHOD: Medical claims data from 2003 to 2008 for employees and their dependents were analyzed. Patients with CRS were included if they had a minimum of 2 CRS-related diagnoses with either radiographic imaging or endoscopy performed between diagnoses. The prevalence and costs of CRS from the payer perspective (reimbursements) were determined. RESULTS: Over 4.9M patients with an average of 3.1 years of eligibility and at least one diagnosis of acute rhinosinusitis (ARS) or CRS were included in the prevalence analysis. 10.7% (95% CI: 10.6% -10.8%) of those with ARS were diagnosed with CRS in the subsequent 5 years. 6.5% of those with CRS were treated with endoscopic sinus surgery (ESS) during this time; the remainder were medically managed. Among those medically managed, after 12 months, over 50% were still consuming care for CRS, and after 24 months, nearly 20% were still doing so. Their costs averaged $1,640 ($1,610 -$1,680) per person-year. In the year prior to ESS, patient care averaged $2,440 ($2,370-$2,520). The ESS procedure plus 45-day post-procedure debridement and medical therapy costs averaged $7,690 ($7,530 -$7,860). In the year following the 45-day post-procedure period, consumption dropped by $1,060 ($967 -$1,150; p Ͻ0.0001). CONCLUSION: A significant proportion of medically managed CRS patients require ongoing treatment for their sinus disease for years. Sinus surgery appears to reduce consumption of sinusitis-related healthcare, but costs related to the procedure are significant.
Decreased Migratory Potential of Treg Cells in CRSwNP
Amanda Munoz, MD (presenter); Kari C Nadeau, MD, PhD; Peter H Hwang, MD OBJECTIVE: The presence of regulatory T cells (Treg) is important for normal immune homeostasis in the airway. We hypothesized that recruitment of Treg into the tissue and chemotactic potential of Treg would be impaired in subjects with CRSwNP. Therefore we tested whether Treg purified from patients with CRSwNP migrated to bronchial epithelial cells (BECs) and primary nasal epithelial cells (PNECs) less than Treg purified from patients with CRSsNP (CRS without NP) and health controls. METHOD: The nasal tissue expression of forkhead box P3 (FOXP3), IL-10, TGF-␤, CCL1, CCL17, and CCL22 were analyzed by means of RT-PCR in 9 healthy controls, 15 CRSwNP, and 15 CRSsNP patients. To determine the infiltration of Treg and T cells in the local biopsied nasal tissue of the same 3 subject groups, nasal sinus mucosa and polyps were stained with FOXP3 and CD3, respectively. Flow cytometry was also used to examine the numbers of Treg in the peripheral blood. Chemotaxis assays were used to evaluate the migration potential of Treg cells onto BECs and PNECs, and toward chemokines (CCL1, CCL17, and CCL22). RESULTS: The average counts for FOXP3ϩ cells in nasal tissue from subjects were significantly decreased in CRSwNP (6.162.75 cells/high power field) compared with controls (11.339.9) and CRSsNP (20.2911.09) in immunohistochemical stains. Expression of FOXP3 transcript was significantly decreased in nasal polyp tissue of CRSwNP (1.080.26, relative fold of mRNA expression) compared with controls (5.890.82) and CRSsNP (3.460.54) patients. Interestingly, CCL1 expression was significantly upregulated in CRSwNP (2.21.42) compared with controls (1.170.74) and CRSsNP (1.421.07) group. However, there were no significant differences in the mean percentage of peripheral blood Treg between CRSwNP and CRSsNP or controls. Migration indices of Treg were significantly decreased in CRSwNP (0.850.20 in BECs, and 1.20.14 in PNECs) patients compared with controls (1.240.54 in BECs, and 1.600.56 in PNECs) and CRSsNP (1.210.36 in BECs, and 1.510.30 in PNECs) group. The migration indices of Treg cells toward CCL1 were significantly decreased in CRSwNP (0.950.16) subjects as compared with CRSsNP subjects (1.370.23) or controls (1.680.68). However, there were no significant differences in chemotaxis potentials toward CCL17 and CCL22 among the groups. CONCLUSION: Our data suggest decreased migration of Treg in subjects with CRSwNP; this may be one of the reasons that infiltration of Treg was decreased by immunohistochemistry in the nasal mucosa of CRSwNP. Lack of Treg presence and therefore function could lead to unchecked proliferation and inflammation in CRSwNP.
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